ClinicalTrials.gg
RecruitingNCT07024225Updated Jun 17, 2025

Colorectal Cancers :A Retrospective Study

An observational study in Colorectal Cancer, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Sohag University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Colorectal Neoplasms with a site in Egypt — 15 open to participants now, 17 under way, 5 of them phase 3. Colorectal Neoplasms · Egypt.

Planned enrollment
11th of 23
100 · median 96
Started
2025
with 4 others
Observational
23 of 55
4 open now
Primary completion
2025-10
later than 6 of 16 live
Registered
43rd of 55
by date
Lead sponsor
6 of 55
Sohag University

Among the 55 studies in Colorectal Neoplasms with a site in Egypt, this one is the 11th largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2025, is one of 23 observational ones, reaches primary completion later than 6 of the 16 other live ones, and was the 43rd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 55 studies in Colorectal Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Colorectal Neoplasms with a site in Egypt, or all of them as a file.
02

Study summary

Clinico-epidemiological and endoscopic characteristics of patients with colorectal cancers:A Retrospective study in Sohag

The aim :

  1. determine the prevalence and clinicopathological pattern of patients with colorectal cancers
  2. interpretative association between risk factors and severity of patient condition to define possible predictors
  3. assess potential association between serum markers, imaging, endoscopic features and underlying condition.
Read the detailed description

Methods :

  1. all data will be obtained from patients as personal history (name, age, sex, occupation,residence , marital status, personal habits), history of illness at diagnosis, presence of diabetes or hypertension and other co-morbidity
  2. general examination as general appearance,vital signs ,head and neck ,chest ,upper and lower limbs, Abdomen and pelvis ,and local examination as per rectal examination.
  3. laboratory test as complete blood count and tumor markers ,imaging as abdominal ultrasound, CT,MRI, endoscopic findings and pathological features.
03

Conditions studied

  • Colorectal Cancer

Keywords

  • Clinical
  • Endoscopic
  • Pathological features
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Study will be carried on patients more than 18 diagnosed as colon or rectal cancer supported by histopathological result

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients aged 18 years old and above
  • patients with confirmed diagnosis of colon or rectal cancer ,supported by histopathological result

Exclusion criteria

Exclusion Criteria:

  • patients with missed pathological or endoscopic data
  • patients diagnosed with other rather than colorectal cancers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with colorectal cancers

    Patients more than 18 years old with colorectal cancers

    Procedure: Endoscope

Interventions

  • ProcedureEndoscope

    Lower endoscopy

06

What researchers measure

Primary outcomes

  1. Number and proportion of patients diagnosed with colon or rectal cancers within study period in sohag, Egypt

    To determine prevalence of colorectal cancers in sohag, Egypt

    Time frame: Retrospective review from 2015 to 2025

  2. Correlation between baseline serum carcinoembryonic antigen (CEA) levels and tumor stage (TNM classification)

    To assess the association between serum CEA levels and disease severity

    Time frame: As recorded at diagnosis

  3. Association between personal risk factors (e.g, age, sex, lifestyle habits, comorbidities) and tumor stage at diagnosis

    To identify risk factors associated with more advanced disease

    Time frame: based on initial diagnosis records from 2015 to 2025

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Oct 2025, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 17, 2025
StartActual
May 26, 2025
Primary completionEst.
Oct 20, 2025
CompletionEst.
Dec 20, 2025
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07024225
Lead sponsor
Sohag University
Responsible party
Khaled Abdelrahman Elsayed (Principal investigator, Sohag University) — Principal investigator
First posted
Jun 17, 2025
Start date
May 26, 2025
Primary completion
Oct 20, 2025 (estimated)
Completion
Dec 20, 2025 (estimated)
Last update
Jun 17, 2025

Study contacts

Khaled A Elsayed
Contact
drkhaled111aboeldahab@gmail.com
01098540058
Ahmed O Ahmed, Lecturer
study director · Sohag faculty of medicine, internal medicine department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion